Phase II, epidemiologic, open-label study of eculizumab in patients with Shiga-toxin producing E. coli haemolytic uraemic syndrome (STEC-HUS)
Latest Information Update: 05 Nov 2013
At a glance
- Drugs Eculizumab (Primary)
- Indications Haemolytic uraemic syndrome; Shiga-toxigenic Escherichia coli infections
- Focus Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 05 Nov 2013 New trial record
- 24 Oct 2013 Alexion Pharmaceuticals continues to analyse longer-term control clinical outcome data from this study, according to a company media release.